Cannabis Oil for Paediatric Epilepsy: New UK Clinical Guidelines
Updated UK clinical guidelines have clarified the use of cannabis-based medicinal products in children and young people with treatment-resistant epilepsy syndromes.
A joint guideline update from the British Paediatric Neurology Association and the Royal College of Paediatrics and Child Health has clarified and expanded clinical recommendations for the use of cannabis-based medicinal products (CBMPs) in children and young people with treatment-resistant epilepsy. The guidelines focus on three primary indications: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Recommended Products and Dosing
The updated guidelines confirm that pharmaceutical-grade cannabidiol oral solution remains the only MHRA-licensed CBMP for paediatric epilepsy indications. Prescribing must be initiated by a specialist paediatric neurologist, with dosing titrated according to body weight and seizure response over a minimum 12-week assessment period.
Key Clinical Recommendations
- Cannabidiol oral solution should be considered after failure of at least four licensed antiepileptic drugs
- Baseline liver function tests are mandatory before initiation and at four and eight weeks
- Concomitant use with clobazam requires careful dose management due to pharmacokinetic interaction
- Withdrawal should be gradual to avoid seizure exacerbation
Access Through NHS
The guidelines note with concern that NHS access remains inconsistent across regions, with some Integrated Care Boards declining to fund treatment despite NICE approval. The guideline authors urge NHS commissioners to implement NICE Technology Appraisal Guidance without restriction.
"For a child in the grip of hundreds of seizures a week, every month of delayed access to an effective treatment represents irreversible neurological harm."
The guidelines will be incorporated into upcoming postgraduate paediatric neurology training curricula.
